Clover Biopharmaceuticals Full Year 2024 Earnings: CN¥0.72 loss per share (vs CN¥0.11 loss in FY 2023)

Clover Biopharmaceuticals (HKG:2197) Full Year 2024 Results

Key Financial Results

• Net loss: CN¥903.4m (loss widened by CN¥764.9m from FY 2023).
• CN¥0.72 loss per share (further deteriorated from CN¥0.11 loss in FY 2023).

Our free stock report includes 4 warning signs investors should be aware of before investing in Clover Biopharmaceuticals. Read for free now.

2197 Products In Clinical Trials

• Phase I: 2.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Clover Biopharmaceuticals shares are down 3.0% from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for Clover Biopharmaceuticals (2 make us uncomfortable!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.